Welcome to ARRO - Anglia Ruskin Research Online - ARRO ...
Docx File 2,637.43KByte
GlaucomaJost B. Jonas, MD(1), Tin Aung MD(2), Rupert R. Bourne, MD(3), Alain M. Bron, MD(4), Robert Ritch, MD(5), Songhomitra Panda-Jonas, MD(1) (1) Department of Ophthalmology, Medical Faculty Mannheim of the Ruprecht-Karls-University of Heidelberg, Germany(2) Singapore Eye Research Institute, Singapore; Singapore National Eye Centre, Singapore; Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore(3) Vision & Eye Research Unit, Anglia Ruskin University, Cambridge, UK(4) Department of Ophthalmology, University Hospital, Dijon, France; Eye and Nutrition Research Group, Bourgogne Franche-Comté University, Dijon, France(5) Einhorn Clinical Research Center, New York Eye and Ear Infirmary of Mount Sinai, New York, NY 10003, USARunning title: GlaucomaKey words: Glaucoma; Open-angle glaucoma; Angle-closure glaucoma; Normal-tension glaucoma; Exfoliation syndrome; Pigment dispersion syndrome; Congenital glaucoma; Trans-lamina cribrosa pressure difference; Trans-lamina cribrosa pressure gradient; Intraocular pressure; Optic nerve head; retinal nerve fiber layer; Optical coherence tomography; Perimetry; Glaucoma surgery; Funding: NoneCorresponding author: Prof. J. Jonas, Universit?ts-Augenklinik, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany; Phone: **49-6221-3929320; e-mail: Jost.Jonas@medma.uni-heidelberg.deSummaryGlaucoma is a heterogeneous group of diseases with an intraocular pressure (IOP) higher than the pressure resistance of the optic nerve head. It is characterized by optic nerve head cupping and visual field damage. It is the most frequent cause of irreversible blindness worldwide with an age-standardized prevalence of 3% in the population aged 40+ years. Chronic glaucomas are painless and symptomatic visual field defects occur late. Early detection by ophthalmological examination is therefore mandatory. The most common risk factors for primary open-angle glaucoma, the most common form of glaucoma, include elevated IOP, older age, Sub-Saharan African ethnicity, positive family history and high myopia. Older age, hyperopia and East Asian ethnicity are main risk factors for primary angle-closure glaucoma. Glaucoma diagnosis is based on ophthalmoscopy, perimetry and tonometry. Therapy is based on medication to lower IOP, laser treatment, and surgical intervention if these treatment modalities fail to prevent progression. IntroductionRanking above other major eye diseases, such as age-related macular degeneration, diabetic retinopathy and myopia, glaucoma is the most frequent cause of irreversible blindness worldwide.1–3 Since chronic open-angle glaucoma is usually painless and can progress unnoticed by the patient until central visual acuity and reading ability are affected late in the disease, early detection is important before subjective symptoms develop. The importance of glaucoma as a public health problem will continue to increase as most glaucomas are age-dependent and the number of older individuals is increasing worldwide due to demographic trends and longer life expectancy.3 This article outlines the epidemiology, pathophysiology, symptoms, diagnosis and therapy, and potential future developments in the field. TerminologyThe term “glaucoma” includes a panoply of diseases which differ in their etiology, risk factors, demographics, symptoms, duration, therapy and prognosis. They have in common a characteristic optic neuropathy underlying irreversible visual loss. The term was used inclusively prior to the increasing discovery of subdivisions, which are themselves distinct diseases with different genetic and pathophysiologic risk factors. Depending on the morphology of the anterior chamber angle (the region between the peripheral cornea and the peripheral iris), glaucoma can be broadly divided into open-angle glaucoma and angle-closure glaucoma (Fig. 1, 2). In open-angle glaucoma, the aqueous humour has free access in the anterior chamber angle to the trabecular meshwork and Schlemm?s canal, through which it leaves the eye. In “secondary” open-angle glaucomas, the outflow resistance through the trabecular meshwork/Schlemm?s canal is increased due to a cause visible on eye examination, such as in pigmentary glaucoma and exfoliative glaucoma.4,5 In primary open-angle glaucoma (POAG) (both “high-tension” and “normal-tension”), no visible cause is evident on examination, but relatively recent and ongoing discoveries are elucidating differences in both genetic parameters and systemic risk factors allowing increasing differentiation of POAG, which was until recently thought of as a single disease. In angle-closure, the peripheral iris is in contact with the trabecular meshwork at levels up to Schwalbe’s line, so that the anterior chamber angle is blocked by iris tissue and the aqueous humour has no access to the outflow system.6,7 In primary angle-closure (PAC, “push” mechanism), the iridocorneal contact is caused by a forward bulging of the peripheral iris, due to an increased pressure difference between the posterior chamber and anterior chamber of the eye, or due to an anatomical predisposition of the morphology of the anterior chamber angle. Primary angle-closure glaucoma (PACG) is present when glaucomatous optic nerve and visual field damage occurs. In secondary angle-closure glaucoma (“pull” mechanism), the iridocorneal contact is caused by the iris being pulled into the angle by causes such as neovascularization in the iris root, usually provoked by ischemic retinopathy (“neovascular glaucoma”), iridocorneal endothelial syndrome, or peripheral anterior synechiae caused by uveitis.8 In congenital glaucoma, the trans-trabecular outflow is reduced, often due to a not (yet) fully developed trabecular meshwork and Schlemm?s canal.9 The increase in intraocular pressure (IOP) in children younger than 2 years results in an enlargement of the globe, also called buphthalmos. EpidemiologyAs reported by the Global Burden of Disease Study, 32.4 million individuals worldwide were blind (defined as visual acuity in the better eye of <3/60) and 191 million individuals were vision impaired (defined as visual acuity in the better eye of <6/18, ≥3/60) in 2010.10 Glaucoma was the cause for blindness in 2.1 million (95% uncertainty interval (UI):1.9, 2.6) people and was the cause for visual impairment in 4.2 million (95% UI:3.7, 5.8). Glaucoma caused 6.6% (95% UI: 5.9, 7.9) of all blindness worldwide in 2010 and 2.2% (95% UI: 2.0, 2.8) of all visual impairment. Due to its association with older age, glaucoma prevalence was lower in regions with younger populations than in high-income regions with relatively old populations. From 1990 to 2010, the number of blind or visually impaired due to glaucoma increased by 0.8 million (95%UI: 0.7, 1.1) or 62% and by 2.3 million (95%UI: 2.1, 3.5) or 83%, respectively. The age-standardized global prevalence of glaucoma related blindness in adults aged 50+ years decreased from 0.2% (95% UI: 0.1, 0.2) in 1990 to 0.1% (95% UI: 0.1, 0.2) in 2010. The age-standardized global prevalence of glaucoma related visual impairment for the same age group increased from 0.2% (95%UI: 0.2, 0.3) to 0.3% (95% UI: 0.2, 0.4). Between 1990 and 2010, the percentage of global blindness and visual impairment caused by glaucoma increased from 4.4% (4.0, 5.1) to 6.6%, and from 1.2% (1.1, 1.5) to 2.2% (2.0, 2.8), respectively. Age-standardized prevalence of glaucoma related blindness and visual impairment did not differ markedly between world regions nor between women (0.1% (95% UI: 0.1, 0.2) and 0.3% (95% UI: 0.2, 0.4), respectively) and men (0.1% (95% UI: 0.1, 0.2) and 0.3% (95% UI:0.3, 0.4), respectively).10In a recent meta-analysis, the global prevalence of glaucoma was 3.54% (95% credible Intervals (CrI), 2.09-5.82) for the population aged 40-80 years.3 POAG with a pooled global prevalence of 3.05% was six times more common than PACG with a pooled global prevalence of 0.50%. The prevalence of POAG was highest in Africa (4.20%; 95% CrI, 2.08-7.35), and the prevalence of PACG was highest in Asia (1.09%; 95% CrI, 0.43-2.32). In 2013, the number of people aged 40-80 years with glaucoma worldwide was assessed to be 64.3 million, predicted to increase to 76 million in 2020 and to 112 million in 2040. Men were more likely to have POAG than women (odds ratio [OR], 1.36; 95% CrI, 1.23-1.52), and people of African ancestry were more likely to have POAG than people of European ancestry (OR, 2.80; 95% CrI, 1.83-4.06). The prevalence of glaucoma-related bilateral blindness or unilateral blindness was higher in the PACG group than in the open-angle glaucoma group, suggesting that PACG has a worse visual outcome and prognosis. Anatomy and PhysiologyIntraocular pressure (normal range: 10-21 mm Hg) is regulated by a balance between the secretion of aqueous humour by the ciliary body in the posterior chamber and its drainage from the anterior chamber angle either through the trabecular meshwork and Schlemm?s canal into the episcleral veins or via the uveoscleral outflow pathway through the iris root into the uveoscleral interface (into the ciliary body?) (Fig. 1, 2). The physiological functions of the aqueous humour include maintaining the IOP to give the eye a constant shape and size (what is of utmost importance for the optical system of the eye), nutrition of the lens and cornea, and heat convection in the anterior chamber. Elevated IOP is due to decreased outflow facility of aqueous humour. In glaucomatous optic neuropathy, typical morphological changes can be detected with ophthalmoscopy in the retinal nerve fiber layer and at the optic nerve head (Fig. 3-5).11–13 The retinal nerve fiber layer inside the eye consists of the retinal ganglion cell (RGC) axons and forms the inner layer of the retina. It is located between the RGC layer on its outer side and the inner limiting membrane as the basal membrane of the retinal Müller cells on its inner side. The optic nerve head (also called optic disc) is the anterior tissue of the optic nerve located 15° nasal to the fovea (the center of the macula). Its diameter is about 1.5 to 2.0 mm. Its area, showing an inter-individual variability of about 1:7, is associated with the ethnic background: Caucasians have on an average smaller optic discs as compared to Chinese, followed by Indians and Africans or individuals of African descent (Fig. 3).15 Its size is constant after about age 15 years, except for highly myopic eyes, in which the optic disc secondarily enlarges in association with the axial elongation of the eye. The RGC axons exit the eye at the optic disc and form the optic nerve posterior to the eye. The optic disc also serves for the exit of the central retinal vein and for entry of the central retinal artery. The base of the optic nerve head consists of the lamina cribrosa, a perforated collagenous sieve-like structure through which the optic nerve fibers and blood vessels take their course, and which is the site at which the damage to the RGC axons/optic nerve fibers occurs in glaucoma (Fig. 6).16 It is the frontier between the intravitreal compartment with the IOP and the retro-laminar compartment with the optic nerve tissue pressure and the retrobulbar cerebrospinal fluid pressure.17 The trans-lamina cribrosa pressure difference has been defined as difference between IOP and retrobulbar pressure, mainly the retrobulbar cerebrospinal fluid pressure.18 Inside the optic disc, the RGC axons form the neuroretinal rim, while the disc center is occupied by the optic cup, a nerve fiber free region. Under physiological conditions, rim size and cup size increase with larger optic disc size. The neuroretinal rim has a characteristic shape following the so called ISNT (inferior–superior–nasal–temporal) rule; it is usually widest in the inferior disc region and superior disc region, and it is thinnest in the temporal disc sector.19 In the retro-laminar region, the RGC axons form the optic nerve, which contains approximately 1.4 million myelinated axons at birth and physiologically loses about 0.3% of these axons per year of age. PathophysiologyIn contrast to a variety of causes for elevated IOP or reasons for increased susceptibility of the optic nerve head to glaucoma whether or not IOP is elevated, all glaucomas have in common typical optic nerve damage, or glaucomatous optic neuropathy, a neurodegenerative disorder. Elevated IOP can be due to specific causes, such as liberation of pigment granules from the iris pigment epithelium, as is the case in both pigment dispersion syndrome/glaucoma and exfoliation syndrome/glaucoma.5 Glaucomas in which a definitive cause is recognizable on slit-lamp examination are termed “secondary” glaucomas.In pigment dispersion syndrome, which has its onset in the second and third decade, the peripheral iris is concave and rubs against the zonular apparatus during accommodation and during pupillary dilation and constriction. It is far more common than previously believed and often goes undiagnosed because of low suspicion of glaucoma in the younger population. It can have an autosomal dominant inheritance and leads to glaucoma in about 10% of affected individuals. Men and women are equally affected but glaucoma is about three times as common in men. Eighty percent of those manifesting signs of the disorder are myopes and 20% emmetropes. Its occurrence in hyperopes is extremely rare, but these people serve as carriers of the gene. The incidence of glaucoma increases in women after menopause. The iridozonular friction between the posterior surface of the iris and zonule fibers of the lens leads to disruption of the iris pigment epithelium and the liberated pigment is deposited on structures throughout the anterior chamber, including the trabecular meshwork, where it may increase aqueous outflow resistance and lead to elevated IOP.20 Exfoliation syndrome is an age-related disease and is the most common recognizable cause of open-angle glaucoma worldwide, accounting for the majority of cases in some countries.4 It is estimated to affect about 80 million people worldwide and is most common in Caucasians. About 1/3 of affected individuals develop glaucoma, which carries a more severe prognosis than POAG. It is characterized by the production, deposition, and progressive accumulation of a white, fibrillar, extracellular material in many ocular tissues, most prominent on the anterior lens surface and pupillary border and represents a generalized disorder of elastic tissue and the extracellular matrix (Fig. 7).21 Rubbing of the iris over the lens causes disruption of the deposited exfoliation material, while the material itself acts like sandpaper, disrupting the iris pigment epithelium and leading to pigment liberation, both of which are deposited in the trabecular meshwork, leading to increased outflow resistance and often markedly elevated IOP. Exfoliation syndrome causes not only open-angle, but also is a prominent cause of angle-closure glaucoma. It is not a “type” or “form” of glaucoma, but the glaucoma is an ocular manifestation of a systemic disorder, and associations with other disorders are being steadily assessed. These disorders include hearing loss, cerebrovascular and cardiovascular disease, and disorders of elastic tissue, including pelvic organ prolapse and inguinal hernia. It is considered a conformational disorder of fibrillin and has been shown to be a disorder of autophagy and mitochondrial dysfunction, similar to other neurodegenerative diseases.22 Two single nucleotide polymorphisms of the LOXL1 gene are present in 99% of affected Caucasians, but a large portion of the unaffected populations, including non-Caucasians, also have these polymorphisms, implying that they are not causative in themselves.23 An additional 5 genes have recently been described. Environmental factors appear also to influence the manifestation of the disease.24 In POAG, aqueous humour outflow resistance is increased to yet unknown factors. The level of IOP varies markedly and reaches down to subnormal values of as low as 10 mmHg. If in the case of POAG, glaucomatous optic nerve damage developed in the presence of statistically normal IOP levels, the condition has also been called normal-pressure glaucoma, showing the full range of POAG. In normal-pressure glaucoma, aqueous outflow resistance is normal or may be slightly increased.In primary angle-closure glaucoma, as mentioned, aqueous humour access to the outflow pathways is blocked by contact with or without adhesions between the peripheral iris and the anterior trabecular meshwork, where Schwalbe’s line forms the boundary between that structure and the cornea. Reasons are an increased pressure difference between the posterior chamber and the anterior chamber due to an increased trans-pupillary flow resistance in association with anatomic parameters, such as an increased lens vault, an enlarged contact area between the posterior iris and the lens surface, and an abnormal insertion of the iris root on the ciliary body (Fig. 1).7 In secondary angle-closure glaucoma, a neovascularization in the anterior chamber has developed as reaction of an ischemic retinopathy, such as proliferative diabetic retinopathy, with formation of vascular endothelial growth factor (VEGF).25 The newly formed blood vessels cover the anterior chamber angle, block the latter by formation of a new basement membrane on the surface, and finally retract the peripheral iris peripheral cornea, irreversibly blocking the anterior chamber angle. The increased IOP, or an IOP higher than the pressure sensitivity of the optic nerve head, can cause mechanical stress and strain on the lamina cribrosa at the bottom of the optic nerve head and on adjacent tissues.16 It may result in compression, deformation, and eventual remodeling of the lamina cribrosa with consequent mechanical axonal damage and disruption of the orthograde and retrograde axonal transport.11,26,27 Disruption of the retrograde axoplasmic flow decreases the delivery of trophic factors from the neurons of the lateral geniculate nucleus to the retinal ganglion cell bodies in the retina.28,29 Animal studies with experimentally induced ocular hypertension demonstrated a blockade of both orthograde and retrograde axonal transport at the level of the lamina cribrosa at an early stage of glaucoma.28,29 A low ocular perfusion pressure, including low systemic blood pressure, has been reported to be associated with glaucomatous optic neuropathy.30–33 Blood pressure follows a diurnal curve distribution, similar to that of IOP, and it is normal for blood pressure to be lower at night, but overdipping is associated with an increased risk for glaucoma progression, and perhaps, development.32,32 We caution general physicians and cardiologists against giving blood pressure lowering medications at bedtime in patients with glaucoma. It has to be considered that the strength of IOP as a risk factor for glaucoma may preclude any useful interpretation of ocular perfusion pressure, defined as difference of diastolic blood pressure minus IOP, in unadjusted statistical analyses, and that after adjusting for IOP the correlations no longer represent the risk caused by ocular perfusion pressure.34 Also, an increase in the central retinal venous pressure in glaucoma was not taken into account when the ocular perfusion pressure was calculated.35 It remains unclear whether the mitochondria located in a high concentration in the pre-laminar region play a direct role in the pathogenesis of glaucomatous optic neuropathy.36,37 In a similar manner, the pathways from gene mutations contributing to glaucoma and the eventual dysfunction of the encoded proteins have not been fully explored yet.38,39 Glaucoma-associated loss of neurons is not limited to the RGCs, but extends into the lateral geniculate nucleus and the visual cortex.40,41 With respect to different classes of RGCs, clinical studies and histological investigations have suggested that the glaucomatous damage affects all subsets of RGCs in a similar manner.40,42,43 Studies also showed that the glaucomatous loss of RGCs and their axons was accompanied by changes in the glial cell population, including astrocytes and the retinal microglial cells.44,45 Risk Factors The main risk factors for both development and progression of glaucoma are an IOP too high relative to the pressure sensitivity of the optic nerve head,46–51 older age,3,52–55 ethnic background,53,56 positive family history for glaucoma, stage of the disease, and high myopia.57–59 In a recent randomized placebo-controlled trial conducted by Garway-Heath and colleagues, medical lowering of IOP resulted in preservation of visual field in patients with open-angle glaucoma.51 A meta-analysis of population-based studies revealed that the odds ratio of the prevalence of POAG was 1.73 (95% CrI, 1.63-1.82) for each decade increase in age beyond age 40.3 Similarly, the prevalence of PACG increases with older age. Across all ethnicities, individuals of African ancestry had the highest prevalence of glaucoma (6.11%; 95% CrI, 3.83-9.13) and POAG (5.40%; 95% CrI, 3.17-8.27), while Asians had the highest prevalence of PACG (1.20%; 95% CrI, 0.46-2.55).3 Gender has been inconsistently associated with the prevalence of open-angle glaucoma, yet two meta-analyses of population-based glaucoma studies reported a higher prevalence of POAG in men than in women with an odds ratio of 1.36 for men.3,53 High myopia with a myopic refractive error of more than -6 diopters or more than -8 diopters is another strong risk factor for glaucoma.57–60 Correspondingly, the Singapore Malay Study Eye showed an association between moderate or higher myopia (worse than -4D) and higher prevalence of POAG.59 Since IOP is often within the normal range and since the myopic appearance of the optic nerve head makes the detection of glaucomatous changes difficult, the diagnosis of glaucomatous optic neuropathy can be missed in myopic eyes. Studies have suggested that the main factor for the myopia-associated increase in glaucoma susceptibility is the myopia associated enlargement of the optic disc.60 Secondary stretching and thinning of the lamina cribrosa in association with an elongation and thinning of the peripapillary scleral flange could lead to marked changes in the biomechanics of the optic nerve head and an increase in the glaucoma susceptibility. Another factor may be the biomechanics of the optic nerve dura mater, which pulls on the peripapillary sclera in eye movements and increases the stress and strain of the lamina cribrosa.61 Socioeconomic status has an influence on the rate of early detection of glaucoma and on the commencement and compliance of therapy.62,63 It is therefore associated with prognosis. It has remained unclear whether nutritional status and diet have an influence on the prevalence and incidence of any type of the glaucomas. In a similar manner, the relationship between POAG and diabetes mellitus,64,65 arterial hypertension,66,67 body mass index,68 obstructive sleep apnea,69 and oral contraceptive use,70 has remained unclear. Although controversial, low cerebrospinal fluid pressure71,72 and low ocular perfusion pressure including a low systemic blood pressure may potentially play a role in glaucoma.30–34,73,74 A thinner central cornea has been considered a risk factor for glaucoma, since a thin cornea leads to falsely low measurements of IOP.52,75,76 Besides being a diagnostic risk factor for the underestimation of IOP and thus for the detection of glaucoma, it was reported that a thin cornea, due to a hypothetical association with a thin lamina cribrosa could additionally be a structural risk factor. An association between corneal thickness and thickness of the lamina cribrosa has however, not been shown yet; in contrast, in a histomorphometric study both parameters were not significantly correlated with each other.77 Correspondingly, corneal biomechanical parameters such as corneal hysteresis and corneal resistance factor were not significantly correlated with the severity of PACG nor was central corneal thickness associated with glaucoma in an East Asian population.78,79The main risk factors for development of PAC are older age, axial hyperopia, East Asian ethnicity, and female sex.6,7,80–83 The main ocular risk factors include a crowded anterior segment in a small eye, with a smaller width, area and volume of the anterior chamber, a thicker and more anteriorly positioned lens, thicker irides with greater iris curvature, and a greater lens vault in association with a short axial length of the eye.80–83 The lack of space in the anterior chamber leads to a higher risk of blockage of the angle by peripheral iris. The obstruction of the angle may occur acutely, leading to acute and painful angle-closure glaucoma, or it may develop chronically, associated with painless chronic angle-closure glaucoma. In addition to biometric parameters of the anterior ocular segment, choroidal expansion has been been reported to be associated with untreated and treated, acute and chronic primary angle closure.84–86 It is unclear, however, whether this finding was a cause or effect of angle-closure. GeneticsSporadic POAG has been found by genome wide association studies (GWAS) to be associated with several genes such as CDKN2B-AS for predominantly normal-pressure glaucoma, CAV1-CAV2, TMCO1, and ABCA1 for high pressure glaucoma, and AFAP1, GAS7, TXNRD2, ATXN2, chromosome 8q22 intergenic region, and SIX1/SIX6 for POAG.87–94 This spectrum of POAG loci was unexpectedly broad. Also, GWAS have identified genetic loci associated with quantitative glaucoma-related traits such as IOP, central corneal thickness and optic disc size.23,93,95–105 Unexpectedly, the number of genetic loci shared between IOP and the POAG phenotype was limited (CAV1-CAV2, TMCO1, ABCA1, and GAS7), suggesting that the genetic susceptibility to POAG was not solely explained by elevated IOP alone. The genetic associations of glaucoma vary according to the ethnic group. Common glaucoma susceptibility alleles that are seen in Caucasians at the genome-wide level (CDKN2B-AS1, TMCO1, CAV1/CAV2, chromosome 8q22 intergenic region, and SIX1/SIX6) appear to have weaker associations with POAG in African-Americans. Thus far, genome wide association studies on PACG implicate 8 genetic loci that showed strong association with disease.38,90 These loci suggest the involvement of cell-cell adhesion (PLEKHA7, FERMT2, and EPDR1), collagen metabolism (COL11A1), type 2 diabetes-related pathway (GLIS3), and acetylcholine-mediated signaling (CHAT) as important in the PACG disease process. Fitting with the results of genetic studies, assessment of family history of glaucoma is clinically important. Having a first-degree relative with glaucoma has been consistently associated with an increased risk for POAG and PACG in prevalence surveys. Siblings of affected individuals have nearly an 8-fold risk of POAG and 5-times risk of angle closure when compared to siblings of unaffected individuals. The risk for POAG may be stronger when the affected relative is a sibling rather than a parent or child. Family linkage studies on patients with a strongly positive family history of glaucoma have implicated broad chromosomal regions showing significant linkage with POAG and congenital glaucoma, many genes of which (such as CYP1B1) show very strong disease penetrance. Genes such as myocilin (MYOC, GLC1A) (CCDS1297.1), optineurin (OPTN, GLC1E) (CCDS7094.1) and WD repeat domain (GLC1G) (CCDS4102.1) are associated with a monogenic, autosomal dominant inheritance.87,88 These genes, however, explain the development of the disease in only less than 10% of all glaucoma patients. To cite an example, the MYOC gene at the GLC1A locus encodes the protein myocilin, mutations of which are generally found in the juvenile or early adult form of POAG with a high IOP. The penetrance for carriers of disease-associated mutations is approximately 90%. In adult patients with POAG without a strong family history however, the prevalence of myocilin mutations varies from 3% to 5%. Glaucoma patients with the OPTN (optineurin) gene mutations have POAG with normal IOP. Optineurin may have a neuroprotective role by reducing the susceptibility of RGCs to apoptotic stimuli.Although a number of genes have been found to be associated with glaucoma, the connection between the gene mutation, the secondary change in the shape of the encoded protein and the tertiary alteration in the function of this protein have remained unclear. The genetic findings therefore have not yet markedly contributed to elucidate the pathogenesis of the glaucomas. Screening for glaucomaA large proportion of glaucoma patients remain undiagnosed in developed, developing, and underdeveloped regions (50-90%).63,106 Although screening for glaucoma in the entire population would be an option, it is not considered logistically feasible. In particular, due to a relatively low prevalence of about 3% in the population aged 40+years, and since diagnostic measures with sufficient diagnostic precision are not yet available, general screening for glaucoma would result in an unacceptable high number of false positive diagnoses. Using a health economic model, Burr and colleagues compared opportunistic case finding to two proposed screening strategies for glaucoma in the United Kingdom.107 They found that general population screening was not cost-effective at the given prevalence rate and that targeted screening of specific subgroups aligned with the established risk factors would be needed in order to achieve cost-effectiveness. It holds true also for genetic screening for glaucoma. It is therefore important to select participants at substantial risk in order for screening programs to be effective. If only one screening technique can be applied, imaging of the optic nerve and retinal nerve fiber layer is currently thought to be the best. A single measurement of IOP has a low sensitivity to detect glaucoma under screening conditions. DiagnosisSince the chronic glaucomas are painless and measurable visual field defects do not develop at an early stage of glaucoma, and since defects often do not occur at homonymous locations in both visual fields, self-detection of glaucoma by affected patients usually occurs at a late stage of the disease. The mainstay of the detection of glaucoma is the examination of the optic nerve head and retinal nerve fiber layer.107–114 Glaucomatous changes of the optic nerve head include loss of neuroretinal rim, leading to enlargement of the optic cup (found otherwise only in eyes after arteritic anterior ischemic optic neuropathy and in few patients with brain tumors close to the inner aperture of the optic nerve canal), deepening of the optic cup (partially reversible if the trans-lamina cribrosa pressure difference reduced to normal or subnormal levels), development and enlargement of parapapillary beta zone, thinning of the retinal nerve fiber layer, and optic disc hemorrhages as signs of progression of the disease. These changes can be assessed by simple ophthalmoscopy or by using imaging techniques such as spectral-domain optical coherence tomography. The latter is particularly useful for follow-up examinations, since by electronically comparing digitized images it can detect glaucoma progression.115,116 Tonometry is an essential part of the diagnosis and follow-up of glaucoma although a relatively large group of patents may have statistically normal IOP measurements.117 The dependence of the tonometric measurements on the central corneal thickness and curvature has to be taken into account.118 In eyes with abnormally thick corneas, tonometry gives falsely high readings, potentially leading to overdiagnosis, and in eyes with abnormally thin corneas, the tonometric measurements are falsely low, with the risk of underdiagnosis of glaucoma. Central corneal thickness and corneal curvature should therefore be measured once, so that the tonometric readings can be corrected accordingly. Perimetric visual field examination is the second pillar in the diagnosis and follow-up of glaucomatous optic nerve damage.46–48 Since a substantial number of optic nerve fibers can be lost before perimetric defects are detected, the diagnostic precision of perimetry increases with the stage of glaucoma.119 The advantage of perimetry is that it describes the subjective psychophysical defect as experienced by the patient. Its disadvantage is a relatively high inter-visit variability so that at least three perimetric examinations may be necessary to reliably detect visual field deterioration. Other psychophysical tests, including assessment of glaucoma-related acquired dyschromatopsis or color vision deficiency, decreased dark adaptation, increased photophobia and decreased contrast sensitivity are of importance for the quality of vision of the patient. These modalities however, are not routinely measured due to a high inter-individual and intra-individual variability.A potential future development is the application of the newly developed optical coherence tomography angiography to visualize the superficial and deep retinal vascular network and in particular the peripapillary radial vascular network.120 Assessment of the latter may be of diagnostic help in the detection and follow-up of glaucomatous optic neuropathy in highly myopic eyes in which most other diagnostic methods fail. Open-angle glaucoma is distinguished from angle-closure glaucoma by gonioscopic examination of the anterior chamber angle. The main characteristic of PACG compared to open-angle glaucoma is that the anterior chamber angle is obstructed by apposition of the iris. Like open-angle glaucoma, angle-closure glaucoma in patients of East Asian ethnicity is predominantly an asymptomatic disease with individuals often unaware they have the disorder until advanced visual loss has occurred. In Caucasian populations, acute angle-closure glaucoma caused by relative pupillary block is more common. It is characterized by an inflamed eye with a pronounced marked hyperemia of the conjunctiva, corneal edema, a mid-dilated unreactive pupil, a shallow anterior chamber, and high IOP. It is usually accompanied by severe ocular pain with blurring of vision with haloes noticed around lights, nausea and vomiting. Therapy Open-angle glaucomaThe only proven and generally accepted therapy to reduce the risk of further progression of glaucomatous optic neuropathy is to lower IOP.49,51,121 IOP reduction is achieved by medical therapy, laser treatment or surgery. The goal is to lower the IOP toward a target level at which further progression of glaucomatous optic nerve damage is unlikely. The target IOP for a particular eye is estimated on the pretreatment IOP, the severity of damage, presence of risk factors for progression, life expectancy, and potential for adverse effects from treatment. One usually aims for an IOP reduction of 20% to 50%. The target pressure is set lower the greater the pre-existing optic nerve damage and the more risk factors present. The target IOP should be estimated on an individual basis and should periodically be re-analyzed by assessing whether the optic nerve damage is stable or progressed. Several categories of topical IOP-lowering drugs are available. The choice of medication is influenced by cost, adverse effects, and dosing schedules. In general, prostaglandin analogues are first-line medical therapy which, delivered once in the evening, lower IOP by improving uveoscleral outflow. Local side effects include elongation and darkening of eyelashes, loss of orbital fat (so-called prostaglandin-associated periorbitopathy) with resulting enophthalmos, iris darkening in eyes with greenish-brown iris color, and periocular skin pigmentation. An alternative to prostaglandins are β-adrenergic blockers, which reduce IOP by decreasing aqueous humour production. Applied once (in the morning) or twice (morning and evening) daily, they can result in systemic side effects including bradycardia, arrhythmias, drop in blood pressure, reduced libido, and increased obstructive bronchial problems that can lead to an asthmatic attack. Beta-blockers are contraindicated in patients with a history of chronic pulmonary obstructive disease, asthma, or bradycardia. Other groups of drugs include topical carbonic anhydrase inhibitors, that reduce aqueous humour production, and α-adrenergic agonists (brimonidine), which decrease aqueous humour production and increase uveoscleral outflow. Miotics, such as pilocarpine, have the longest history of application and reduce IOP by improving the trans-trabecular outflow. Local side-effects are a varying degree of annoying involuntary accommodation in patients younger than 40 years and pupillary constriction. The latter is inconvenient at night and can reduce visual acuity in eyes with cataract, increases however the depth of focus due to the stenopeic effect. Miotics can therefore be useful in eyes with artificial intraocular lenses after cataract surgery. Miotics do not have major systemic side effects. Prostaglandin analogues, carbonic anhydrase inhibitors and miotics reduce IOP during both day and night, while β-adrenergic blockers and α-adrenergic agonists are effective mostly during daytime. Most drug groups can be combined with each other. A new class of topically applied drugs are rho-kinase inhibitors which have finished a phase 3 trial and are expected to be approved in 2016.122–124 They reduce IOP by increasing the trans-trabecular outflow, and potentially by additionally decreasing the production of aqueous humour. To decrease the systemic side effects of topically applied eye drops, it is recommended to use gentle occlusion of the lower lacrimal duct or just to close the eyes for a few minutes. These measures markedly reduce the amount of drug passing through the lacrimal drainage system onto the mucosa of the oropharynx where the drugs are easily absorbed and, by avoiding breakdown by the hepatic system, can lead to systemic side-effects. Non-ophthalmic doctors should take into account the possibility of systemic side effects of topically applied ophthalmic drugs, in particular of topical β-blockers, and may encourage the patients to take the drugs and increase their adherence. In eyes with an open anterior chamber angle, medical therapy may be augmented by, or in some cases replaced by, laser therapy (laser trabeculoplasty) to the trabecular meshwork, in particular if the target IOP is not achieved by medical therapy. It holds true in particular in poorly compliant patients. Independently of a concurrent medical therapy, this laser intervention can reduce the IOP by few additional mmHg. The excellent safety profile of the laser therapy is combined with a relatively low efficacy. If the IOP lowering effect is not sufficient, incisional glaucoma surgery has to be performed, usually under local or occasionally under topical anesthesia. In patients with poor compliance or those intolerant to medical therapy, incisional surgery can also be performed as the first step in the glaucoma therapy. A whole panoply of surgical anti-glaucomatous procedures has been developed in the last decade. Creating an additional outflow pathway for the aqueous humour out of the eye, all these surgical techniques such as trabeculectomy risk reduced long-term success secondary to fibrosis around the exit point of the fistula. During and after surgery, anti-metabolites are applied to the surgical site to decrease the fibrotic response and to keep the fistula site open. Glaucoma implant drainage devices are another surgical option and act by channeling the aqueous humour through a tube out of the eye into the subconjunctival space. These devices are similarly effective in lowering IOP to trabeculectomy.125 More recently, so-called minimally invasive glaucoma surgeries (MIGS) show, as compared with standard trabeculectomy, a combination of fewer side effects but lower efficacy. 126 In general, these minimally invasive glaucoma surgeries have not the same IOP–lowering efficacy and a lower risk profile as compared with trabeculectomy. In a similar manner, trabeculectomy as compared with non-penetrating surgeries (deep sclerectomy, viscocanalostomy, and canaloplasty) was more effective in reducing the IOP and carried a higher risk of complications.126,127 Primary angle-closure glaucomaThe therapy of acute angle closure differs profoundly from the therapeutic regime in open-angle glaucoma. In acute angle closure, acutely elevated IOP is classically first lowered by medication, including miotics as first-line drugs (repeatedly instilled in short intervals) and other drugs used in chronic open-angle glaucoma. The aim is open up the angle by inducing a miosis and pulling the peripheral iris tissue out of the angle. An alternative may be immediate laser iridoplasty.128 As definitive treatment, laser peripheral iridotomy, which creates a pathway for aqueous flow between the posterior chamber and anterior chamber by creating a small hole in the peripheral iris is mandatory for all patients with angle-closure. It reduces the pressure differences between both chambers, so that the peripheral iris can flatten and can be retracted out of the anterior chamber angle. If performed at an early stage, a single procedure can result in lifelong cure. If the procedure is delayed, peripheral anterior synechiae may form, and if not released by a surgical intervention within few days to weeks, further circumferential adhesions occur resulting in an irreversible block of the anterior chamber angle and the outflow system. In some cases in which mechanisms other than pupillary block are present (plateau iris syndrome, phacomorphic angle-closure), continued appositional closure of the angle is common. In these cases, laser peripheral iridoplasty can succeed in opening the angle. It does not break peripheral anterior synechiae, which may progress if appositional closure is not relieved.129 Non-pupillary block mechanisms, such as plateau iris, may cause a considerable proportion of angle closure in East Asians, an ethnic group which has a higher propensity for angle-closure glaucoma. Post-iridotomy procedures to further lower IOP are similar to those performed for the therapy of open-angle glaucoma. Since the risk of acute angle closure is usually similar between both eyes, laser peripheral iridotomy should be performed prophylactically in the contralateral eye of a patient presenting with unilateral angle closure. There is currently increased interest in clear corneal cataract extraction for primary angle-closure, particularly in areas of East Asia where adequate diagnostic gonioscopy and laser treatment are not readily available. 130 If laser periphery iridotomy fails to normalize the IOP, in particular due to persisting peripheral anterior synechiae between iris and cornea, combined cataract surgery and goniosynechialysis, a procedure to free the angle of peripheral anterior synechiae and expose the trabecular meshwork to aqueous humour in the anterior chamber, can be successful if the peripheral anterior synechiae are less than about 1 year old.131 If the IOP is not sufficiently lowered, topical anti-glaucomatous medication can be applied and incisional anti-glaucoma surgery, including trabeculectomy or lens extraction with implantation of glaucoma drainage implants, can be carried out. Congenital glaucomaTherapy of congenital glaucomas is primarily surgical by procedures such as goniotomy or trabeculotomy, in which the inner wall of Schlemm?s canal is opened into the anterior chamber. Future developments: - The observed increase in the prevalence of cataract surgery and the increase in the prevalence of axial myopia in particular in Asia may decrease the occurrence of angle-closure glaucoma in the future.132 Studies that investigate the benefits of iridotomy in East Asian patients with angle closure will hopefully provide guidance on the efficacy of this treatment in these populations where angle closure is relatively prevalent among adults.133 - As discussed above, topically applied rho-kinase inhibitors may become an additional pillar in the medical therapy of glaucoma.122–124 Novel sustained-release delivery systems such as intracameral injection of slow-release IOP-lowering drug pellets or topically applied cyclodextrins are being tested in trials.134 Such systems may reduce the problems associated with poor adherence and ocular surface damage that may occur with long-term use of topically applied eye drops.- Improved understanding of patient-reported experience and outcomes is of great importance with this disease that is a cause of great anxiety and which consumes enormous resources within health economies.135 - Better awareness of the disease among the public and healthcare professionals will hopefully address the large proportion of glaucoma that remains undetected even in high-income countries.106 Encouragement of adults with a family history of glaucoma to seek an ophthalmological examination is an important first step in this regard. - Future research will further refine the morphological diagnosis, in particular the measurement of the thickness of the retinal nerve fiber layer and the width of the neuroretinal rim to further improve precision in detecting progression of glaucomatous optic nerve damage. This can be facilitated by combining structural with functional measurements based on perimetry. Early recognition of deterioration of the disease can then prompt changes in treatment or efforts to improve compliance. 111–116 - Since the optic nerve is a fascicle of the brain and thus part of the central nervous system, it is surrounded by the optic nerve meninges and it is imbedded into cerebrospinal fluid. The orbital cerebrospinal fluid pressure is thus the retro-ocular counter-pressure to the IOP.18 Future studies may assess the hypothesis that in patients with POAG and normal IOP values, the orbital cerebrospinal fluid could be abnormally low, so that the trans-lamina cribrosa pressure difference was elevated.71,72 - Future research into the pathogenesis of POAG include exploration of the secondary involvement of the retinal microglial cells in the process of RGC damage;136 elucidation of secondary intracranial changes including cerebral neuroplasticity;42 examination of the role of retinal vein pulsations and retinal venous blood pressure in the pathogenesis and diagnosis of glaucomatous optic neuropathy;137 assessment of the etiology of parapapillary beta zone;138 investigations of the reasons for the increased glaucoma susceptibility in high myopia; 57,112 examination of the biomechanics of the optic nerve dura mater and its influence on the optic nerve head.61,139 - Exfoliation syndrome is a protean disorder and is potentially preventable or reversible. New research into the genetics, proteomics, molecular biology and cellular processes of this disease have led to more insight into the cell biology of this disorder may further open novel approaches to therapy.140- Possible novel future therapies include induction of a re-sprouting of RGC dendrites to increase the receptive field of the still existing ganglion cells;141 development of devices (including those intraocularly implanted) to deliver long-term slow-release of anti-glaucoma medications;14^2 to develop refinements of the existing surgical technique to reduce the risk of a postoperative scarification of the filtering bleb leading to a treatment failure; and to further assess the application of stem cells and gene therapy.Search strategy and selection criteria: We systematically searched the Cochrane Library (2000-2016), MEDLINE (2000-2016), and EMBASE (2000-2016) and used the search words of glaucoma, primary open-angle glaucoma, secondary open-angle glaucoma, angle-closure glaucoma, intraocular pressure, optical coherence tomography, perimetry, optic disc, optic nerve head, retinal nerve fiber layer, trabecular meshwork, glaucoma therapy, and glaucoma surgery. We largely selected publications in the past 5 years, but did not exclude commonly referenced and highly regarded older publications. We also searched the reference lists of articles identified by this search strategy and selected those we judged relevant. Review articles and book chapters are cited to provide readers with more details and more references than this Seminar has room for. Our reference list was modified on the basis of comments from peer reviewers.”Competing interest statement- Jost B. Jonas: Consultant for Mundipharma Co. (Cambridge, UK); patent holder with Biocompatibles UK Ltd. (Franham, Surrey, UK) (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and / or anti-angiogenic factor; Patent number: 20120263794), and patent application with University of Heidelberg (Heidelberg, Germany) (Title: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; Europ?ische Patentanmeldung 15 000 771.4). - Tin Aung: Alcon: Consultant, Lecture fees/travel, research support; Allergan: Consultant, Lecture fees/travel, research support; Belkin Lasers: Consultant; Carl Zeiss Meditec: Consultant, Lecture fees, research support; Ellex: research support; Ocular Therapeutics: Research support; Pfizer: Consultant, Lecture fees/travel; Roche: Consultant, Lecture fees/travel, research support; Quark: Consultant, research support; Santen, Inc.: Consultant, Lecture fees/travel, research support; Tomey: Lecture fees/travel, research support.- Rupert Bourne: Consultant, Lecture fees/travel, research support: Allergan; Consultant, Lecture fees/travel: Santen; Consultant, Lecture fees/travel, Research support: Tomey.- Alain M. Bron: Consultant for Allergan (Irvine, CA, USA), Bausch-Lomb (Montpellier, France), Théa (Clermont-Ferrand, France). Research grants from Théa and Horus (Nice, France).- Robert Ritch: Personal fees from Sensimed AG (Lausanne, Switzerland), personal fees from iSonic Medical, Inc. (Paris, France), personal fees from Aeon Astron Europe B.V. (Leiden Netherlands), other from Diopsys, Inc. (Pine Brook, NJ, USA), other from GLIA, LLC (Centreville, MD, USA), other from Guardion Health Sciences (San Diego, CA, USA), other from Mobius Therapeutics (St. Louis, MO, USA), other from Intelon Optics, Inc. (Fresh Pond, PI, USA), personal fees f\rom Santen Pharmaceutical Co., Ltd. (Osaka, Japan), personal fees from Ocular Instruments, Inc. (Bellevue, WA, USA), other from Xoma (US) LLC (Berkely, CA, USA), other from The International Eye Wellness Institute, Inc. (Hudson, Ohio, USA), personal fees from Gerson Lehrman Group (New York, NY, USA), personal fees from Gillis Zago Professional Corporation (Brampton, ON, Canada), personal fees from Donahey Defossez & Beausay, personal fees from Tanoury, Nauts, McKinney & Garbarino, PLLC (Columbus, Ohio, USA), outside the submitted work. In addition, Dr. Ritch has a patent GLAUCOVITE with royalties paid to The International Eye Wellness Institute, Inc. (Hudson, Ohio, USA).- Songhomitra Panda-Jonas: Patent holder with Biocompatible UK Ltd. (Title: Treatment of eye diseases using encapsulated cells encoding and secreting neuroprotective factor and / or anti-angiogenic factor; Patent number: 20120263794), and patent application with university of Heidelberg (Title: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; Europ?ische Patentanmeldung 15 000 771.4).References1Bourne RR, Stevens GA, White RA, et al.; on behalf of the Vision Loss Expert Group. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health 2013; 1: e339–e49.2Stevens G, White R, Flaxman SR, et al. Global prevalence of visual impairment and blindness: magnitude and temporal trends, 1990-2010. Ophthalmology 2013; 120: 2377–84.3Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014; 121: 2081–90.4Ritch R. Exfoliation syndrome: The most common identifiable cause of open-angle glaucoma. J Glaucoma 1994; 3: 176–8.5Moroi SE, Lark KK, Sieving PA, et al. Long anterior zonules and pigment dispersion. Am J Ophthalmol 2003; 136:1176–8.6Congdon NG, Youlin Q, Quigley H, et al. Biometry and primary angle-closure glaucoma among Chinese, white, and black populations. Ophthalmology 1997;104: 1489–95.7Nongpiur ME, He M, Amerasinghe N, et al. Lens vault, thickness, and position in Chinese subjects with angle closure. Ophthalmology 2011;118: 474–9.8Dandona L, Dandona R, Mandal P, et al. Angle-closure glaucoma in an urban population in southern India. The Andhra Pradesh eye disease study. Ophthalmology 2000;107: 1710–6.9Ko F, Papadopoulos M, Khaw PT. Primary congenital glaucoma. Prog Brain Res 2015; 221: 177–89. 10Bourne RR, Taylor HR, Flaxman SR, et al. Number of people blind or visually impaired by glaucoma worldwide and in world regions. A meta-analysis. PLoS One 2016; 11: e0162229.11Quigley HA, Katz J, Derick RJ, Gilbert D, Sommer A. An evaluation of optic disc and nerve fiber layer examinations in monitoring progression of early glaucoma damage. Ophthalmology 1992; 99: 19–28.12Schuman JS, Hee MR, Puliafito CA, et al. Quantification of nerve fiber layer thickness in normal and glaucomatous eyes using optical coherence tomography. Arch Ophthalmol 1995; 113: 586–96.13Zangwill LM, Bowd C, Berry CC, et al. Discriminating between normal and glaucomatous eyes using the Heidelberg Retina Tomograph, GDx Nerve Fiber Analyzer, and Optical Coherence Tomograph. Arch Ophthalmol 2001; 119: 985–93.15Varma R, Tielsch JM, Quigley HA, et al. Race-, age-, gender-, and refractive error-related differences in the normal optic disc. Arch Ophthalmol 1994; 112: 1068–76.16Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma, II: the site of injury and susceptibility to damage. Arch Ophthalmol 1981; 99: 635–49. 17Lockwood H, Reynaud J, Gardiner S, et al. Lamina cribrosa microarchitecture in normal monkey eyes part 1: methods and initial results. Invest Ophthalmol Vis Sci 2015; 56: 1618–37.18Morgan WH, Yu DY, Balaratnasingam C. The role of cerebrospinal fluid pressure in glaucoma pathophysiology: the dark side of the optic disc. J Glaucoma 2008; 17: 408–13.19Jonas JB, Gusek GC, Naumann GO. Optic disc, cup and neuroretinal rim size, configuration and correlations in normal eyes. Invest Ophthalmol Vis Sci 1988; 29: 1151–8.20Ritch R: Pigment dispersion syndrome – update 2003. In: Grehn F, Stamper R, eds. Glaucoma. Springer-Verlag, Berlin, 2004:177–92.21Ritch R, Schl?tzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol 2001; 45: 265–315.22Want A, Gillesie SR, Gordon R, et al. Autophagy and mitochondrial dysfunction in Tenon fibroblasts from exfoliation glaucoma patients. PLOS One 2016; 11: e0157404.23Aung T, Ozaki M, Mizoguchi T, et al. . A common variant mapping to CACNA1A is associated with susceptibility to exfoliation syndrome. Nat Genet 2015; 47: 387–92. 24Dewundara S, Pasquale LR. Exfoliation syndrome: a disease with an environmental component. Curr Opin Ophthalmol. 2015; 26: 78–81. 25Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331: 1480–7.26Yang H, Ren R, Lockwood H, et al. The Connective Tissue Components of Optic Nerve Head Cupping in Monkey Experimental Glaucoma Part 1: Global Change. Invest Ophthalmol Vis Sci 2015; 56: 7661–78.27Sigal IA, Yang H, Roberts MD, et al. IOP-induced lamina cribrosa deformation and scleral canal expansion: independent or related? Invest Ophthalmol Vis Sci 2011; 52: 9023–32.28Quigley HA, McKinnon SJ, Zack DJ, et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci 2000; 41: 3460–66.29Abbott CJ, Choe TE, Lusardi TA, Burgoyne CF, Wang L, Fortune B. Evaluation of retinal nerve fiber layer thickness and axonal transport 1 and 2 weeks after 8 hours of acute intraocular pressure elevation in rats. Invest Ophthalmol Vis Sci 2014;55: 674–87.30Tielsch JM, Katz J, Sommer A, Quigley HA, Javitt JC. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol 1995; 113: 216–21.31Zheng Y, Wong TY, Mitchell P, Friedman DS, He M, Aung T. Distribution of ocular perfusion pressure and its relationship with open-angle glaucoma: the Singapore Malay Eye Study. Invest Ophthalmol Vis Sci 2010; 51: 3399–404.32Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol 1994; 117: 603–24.33Charlson M, De Moraes CG, Link AR, et al. Nocturnal systemic hypotension increases the risk of glaucoma progression. Ophthalmology 2014; 121: 2004–12.34Khawaja AP, Crabb DP, Jansonius NM. The role of ocular perfusion pressure in glaucoma cannot be studied with multivariable regression analysis applied to surrogates. Invest Ophthalmol Vis Sci 2013; 54: 4619–20.35Stodtmeister R, Ventzke S, Spoerl E, et al. Enhanced pressure in the central retinal vein decreases the perfusion pressure in the prelaminar region of the optic nerve head. Invest Ophthalmol Vis Sci 2013; 54: 4698–704.36Osborne NN, Nú?ez-?lvarez C, Del Olmo-Aguado S. The effect of visual blue light on mitochondrial function associated with retinal ganglions cells. Exp Eye Res 2014; 128: 8–14.37Sanchez MI, Crowston JG, Mackey DA, Trounce IA. Emerging mitochondrial therapeutic targets in optic neuropathies. Pharmacol Ther 2016; 165: 132–52.38Khor CC, Do T, Jia H, et al. Genome-wide association study identifies five new susceptibility loci for primary angle closure glaucoma. Nat Genet 2016; 48: 556–62.39Bailey JN, Loomis SJ, Kang JH, et al. Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. Nat Genet 2016; 48: 189–94.40Yucel YH, Zhang Q, Gupta N, Kaufman PL, Weinreb RN. Loss of neurons in magnocellular and parvocellular layers of the lateral geniculate nucleus in glaucoma. Arch Ophthalmol 2000; 118: 378–84.41Crawford ML, Harwerth RS, Smith EL 3rd, Mills S, Ewing B. Experimental glaucoma in primates: changes in cytochrome oxidase blobs in V1 cortex. Invest Ophthalmol Vis Sci 2001; 42: 358–64.42Gupta N, Ang LC, No?l de Tilly L, Bidaisee L, Yücel YH. Human glaucoma and neural degeneration in intracranial optic nerve, lateral geniculate nucleus, and visual cortex. Br J Ophthalmol 2006; 90: 674–8.43Sample PA, Bosworth CF, Blumenthal EZ, Girkin C, Weinreb RN. Visual function-specific perimetry for indirect comparison of different ganglion cell populations in glaucoma. Invest Ophthalmol Vis Sci 2000; 41: 1783–90.44Pena JD, Agapova O, Gabelt BT, et al. Increased elastin expression in astrocytes of the lamina cribrosa in response to elevated intraocular pressure. Invest Ophthalmol Vis Sci 2001; 42: 2303–14.45Wang L, Cioffi GA, Cull G, Dong J, Fortune B. Immunohistologic evidence for retinal glial cell changes in human glaucoma. Invest Ophthalmol Vis Sci 2002; 43: 1088–94.46Drance S, Anderson DR, Schulzer M; Collaborative Normal-Tension Glaucoma Study Group. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 2001; 131: 699–708.47The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000; 130: 429–40.48Musch DC, Gillespie BW, Lichter PR, Niziol LM, Janz NK; CIGTS Study Investigators. Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology 2009; 116: 200–7. 49Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701–13.50Leske MC, Heijl A, Hyman L, et al; EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007; 114: 1965–72.51Garway-Heath DF, Crabb DP, Bunce C, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet 2015; 385: 1295–304. 52Heijl A, Bengtsson B, Hyman L, Leske MC; Early Manifest Glaucoma Trial Group. Natural history of open-angle glaucoma. Ophthalmology 2009; 116: 2271–6.53Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci 2006; 47: 4254–61.54Kim M, Kim TW, Park KH, Kim JM. Risk factors for primary open-angle glaucoma in South Korea: the Namil study. Jpn J Ophthalmol. 2012; 56: 324–9. 55Kim KE, Kim MJ, Park KH, et al. Prevalence, awareness, and risk factors of primary open-angle glaucoma: Korea National Health and Nutrition Examination Survey 2008-2011. Ophthalmology 2016; 123: 532–41.56Leske MC, Wu SY, Honkanen R, et al; Barbados Eye Studies Group. Nine-year incidence of open-angle glaucoma in the Barbados Eye Studies. Ophthalmology 2007; 114: 1058–64.57Xu L, Wang Y, Wang S, Wang Y, Jonas JB. High myopia and glaucoma susceptibility the Beijing Eye Study. Ophthalmology 2007; 114: 216–20. 58Qiu M, Wang SY, Singh K, Lin SC. Association between myopia and glaucoma in the United States population. Invest Ophthalmol Vis Sci 2013; 54: 830–35.59Perera SA, Wong TY, Tay WT, Foster PJ, Saw SM, Aung T. Refractive error, axial dimensions and primary open angle glaucoma: The Singapore Malay Eye Study. Arch Ophthalmol 2010; 128: 900–5.60Nagaoka N, Jonas JB, Morohoshi K, et al. Glaucomatous-type optic discs in high myopia. PLoS One 2015; 10: e0138825. 61Wang X, Rumpel H, Lim WE, et al. Finite element analysis predicts large optic nerve head strains during horizontal eye movements. Invest Ophthalmol Vis Sci 2016; 57: 2452–62.62Zhang X, Beckles GL, Chou CF, et al. Socioeconomic disparity in use of eye care services among US adults with age-related eye diseases: National Health Interview Survey, 2002 and 2008. JAMA Ophthalmol 2013; 131: 1198–206.63Topouzis F, Coleman AL, Harris A, et al. Factors associated with undiagnosed open-angle glaucoma: the Thessaloniki Eye Study. Am J Ophthalmol 2008; 145: 327–35.64Zhao D, Cho J, Kim MH, Friedman DS, Guallar E. Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis. Ophthalmology 2015; 122: 72–8. 65Zhou M, Wang W, Huang W, Zhang X. Diabetes mellitus as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. PLoS One 2014; 9: e102972. 66Bae HW, Lee N, Lee HS, Hong S, Seong GJ, Kim CY. Systemic hypertension as a risk factor for open-angle glaucoma: a meta-analysis of population-based studies. PLoS One 2014; 9: e108226.67Zhao D, Cho J, Kim MH, Guallar E. The association of blood pressure and primary open-angle glaucoma: a meta-analysis. Am J Ophthalmol 2014; 158: 615–27.68Kang JH, Loomis SJ, Rosner BA, Wiggs JL, Pasquale LR. Comparison of risk factor profiles for primary open-angle glaucoma subtypes defined by pattern of visual field loss: A prospective study. Invest Ophthalmol Vis Sci 2015; 56: 2439–48.69Zhao XJ, Yang CC, Zhang JC, Zheng H, Liu PP, Li Q. Obstructive sleep apnea and retinal nerve fiber layer thickness: A meta-analysis. J Glaucoma 2016; 25: e413–8.70Wang YE, Kakigi C, Barbosa D, et al. Oral contraceptive use and prevalence of self-reported glaucoma or ocular hypertension in the United States. Ophthalmology 2016; 123: 729–36.71Morgan WH, Yu DY, Cooper RL, Alder VA, Cringle SJ, Constable IJ. The influence of cerebrospinal fluid pressure on the lamina cribrosa tissue pressure gradient. Invest Ophthalmol Vis Sci 1995; 36: 1163–72.72Berdahl JP, Fautsch MP, Stinnett SS, Allingham RR. Intracranial pressure in primary open angle glaucoma, normal tension glaucoma, and ocular hypertension: a case-control study. Invest Ophthalmol Vis Sci 2008; 49: 5412–8. 73De Moraes CG, Liebmann JM, Greenfield DS, et al.; Low-pressure Glaucoma Treatment Study Group. Risk factors for visual field progression in the low-pressure glaucoma treatment study. Am J Ophthalmol 2012; 154: 702–11. 74Topouzis F, Wilson MR, Harris A, et al. Association of open-angle glaucoma with perfusion pressure status in the Thessaloniki Eye Study. Am J Ophthalmol 2013; 155: 843–51.75Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120: 714–20.76Copt RP, Thomas R, Mermoud A. Corneal thickness in ocular hypertension, primary open-angle glaucoma, and normal tension glaucoma. Arch Ophthalmol 1999;117: 14–6.77Jonas JB, Holbach L. Central corneal thickness and thickness of the lamina cribrosa in human eyes. Invest Ophthalmol Vis Sci 2005; 46: 1275–9.78Nongpiur ME, Png O, Chiew JW, et al. Lack of association between corneal hysteresis and corneal resistance factor with glaucoma severity in primary angle closure Glaucoma. Invest Ophthalmol Vis Sci 2015; 56: 6879–85.79Day AC, Machin D, Aung T, et al. Central corneal thickness and glaucoma in East Asian people. Invest Ophthalmol Vis Sci 2011; 52: 8407–12. 80Lavanya R, Wong TY, Friedman DS, et al. Determinants of angle closure in older Singaporeans. Arch Ophthalmol 2008; 126: 686–691. 81Ozaki M, Nongpiur ME, Aung T, He M, Mizoguchi T. Increased lens vault as a risk factor for angle closure: confirmation in a Japanese population. Graefes Arch Clin Exp Ophthalmol 2012;250: 1863–8.82Foo LL, Nongpiur ME, Allen JC, et al. Determinants of angle width in Chinese Singaporeans. Ophthalmology 2012;119: 278–82. 83Moghimi S, Ramezani F, He M, Coleman AL, Lin SC. Comparison of anterior segment-optical coherence tomography parameters in phacomorphic angle closure and acute angle closure eyes. Invest Ophthalmol Vis Sci 2015; 56: 7611–7.84Arora KS, Jefferys JL, Maul EA, Quigley HA. The choroid is thicker in angle closure than in open angle and control eyes. Invest Ophthalmol Vis Sci 2012; 53: 7813–8. 85Zhou M, Wang W, Ding X, et al. Choroidal thickness in fellow eyes of patients with acute primary angle-closure measured by enhanced depth imaging spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci 2013; 54: 1971–8.86Huang W, Wang W, Gao X, et al. Choroidal thickness in the subtypes of angle closure: an EDI-OCT study. Invest Ophthalmol Vis Sci 2013; 54: 7849–53.87Stone EM, Fingert JH, Alward WL, et al. Identification of a gene that causes primary open angle glaucoma. Science 1997; 275: 668–70.88Rezaie T, Child A, Hitchings R, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science 2002; 295: 1077–9.89Thorleifsson G, Walters GB, Hewitt AW, et al. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. Nat Genet 2010; 42: 906–9.90Vithana EN, Khor CC, Qiao C, et al. Genome-wide association analyses identify three new susceptibility loci for primary angle closure glaucoma. Nat Genet 2012; 44: 1142–6.91Gharahkhani P, Burdon KP, Fogarty R, et al. Common variants near ABCA1, AFAP1 and GMDS confer risk of primary open-angle glaucoma. Nat Genet 2014; 46: 1120–5.92Chen Y, Lin Y, Vithana EN, et al. Common variants near ABCA1 and in PMM2 are associated with primary open-angle glaucoma. Nat Genet 2014; 46: 1115–9.93Hysi PG, Cheng CY, Springelkamp H, et al. Genome-wide analysis of multi-ancestry cohorts identifies new loci influencing intraocular pressure and susceptibility to glaucoma. Nat Genet 2014; 46: 1126–30.94Trikha S, Saffari E, Nongpiur M, et al. A genetic variant in TGFBR3-CDC7 is associated with visual field progression in primary open-angle glaucoma patients from Singapore. Ophthalmology 2015; 122: 2416–22.95Cornes BK, Khor CC, Nongpiur ME, et al. Identification of four novel variants that influence central corneal thickness in multi-ethnic Asian populations. Hum Mol Genet 2012;21: 437–45.96Ramdas WD, van Koolwijk LM, Ikram MK, et al. A genome-wide association study of optic disc parameters. PLoS Genet 2010;6: e1000978.97Macgregor S, Hewitt AW, Hysi PG, et al. Genome-wide association identifies ATOH7 as a major gene determining human optic disc size. Hum Mol Genet 2010;19: 2716–24.98Philomenadin FS, Asokan R, N V, George R, Lingam V, Sarangapani S. Genetic association of SNPs near ATOH7, CARD10, CDKN2B, CDC7 and SIX1/SIX6 with the endophenotypes of primary open angle glaucoma in Indian population. PLoS One 2015; 10: e0119703.99Nag A, Venturini C, Small KS; et al. A genome-wide association study of intra-ocular pressure suggests a novel association in the gene FAM125B in the TwinsUK cohort. Hum Mol Genet 2014; 23: 3343–8.100Springelkamp H, H?hn R, Mishra A, et al. Meta-analysis of genome-wide association studies identifies novel loci that influence cupping and the glaucomatous process. Nat Commun 2014; 5: 4883.101Springelkamp H, Mishra A, Hysi PG, et al. Meta-analysis of genome-wide association studies identifies novel loci associated with optic disc morphology. Genet Epidemiol 2015;39: 207–16.102Li Z, Allingham RR, Nakano M, et al. A common variant near TGFBR3 is associated with primary open angle glaucoma. Hum Mol Genet 2015; 24: 3880–92.103Tham YC, Liao J, Vithana EN, et al. Aggregate effects of intraocular pressure and cup-to-disc ratio genetic variants on glaucoma in a multiethnic Asian population. Ophthalmology 2015; 122: 1149–57. 104Springelkamp H, Iglesias AI, Mishra A, et al. New insights into the genetics of primary open-angle glaucoma based on meta-analyses of intraocular pressure and optic disc characteristics. Hum Mol Gen 2016; In Print105Nongpiur ME, Khor CC, Jia H, et al. ABCC5, a gene that influences the anterior chamber depth, is associated with primary angle closure glaucoma. PLoS Genet 2014;10: e1004089.106Shaikh Y, Yu F, Coleman AL. Burden of undetected and untreated glaucoma in the United States. Am J Ophthalmol 2014; 158: 1121–9.107Burr JM, Mowatt G, Hernández R, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess 2007;11: iii-iv, ix-x, 1-190.108Lee KY, Tomidokoro A, Sakata R, et al. Cross-sectional anatomic configurations of peripapillary atrophy evaluated with spectral domain-optical coherence tomography. Invest Ophthalmol Vis Sci 2010; 51: 666–71.109Akagi T, Hangai M, Kimura Y, et al. Peripapillary scleral deformation and retinal nerve fiber damage in high myopia assessed with swept-source optical coherence tomography. Am J Ophthalmol 2013; 155: 927–36. 110Chauhan BC, O'Leary N, Almobarak FA, et al. Enhanced detection of open-angle glaucoma with an anatomically accurate optical coherence tomography-derived neuroretinal rim parameter. Ophthalmology 2013; 120: 535–43. 111Loewen NA, Zhang X, Tan O, et al.; Advanced Imaging for Glaucoma Study Group. Combining measurements from three anatomical areas for glaucoma diagnosis using Fourier-domain optical coherence tomography. Br J Ophthalmol 2015; 99: 1224–9.112Skaat A, De Moraes CG, Bowd C, et al.; Diagnostic Innovations in Glaucoma Study and African Descent and Glaucoma Evaluation Study Groups. African Descent and Glaucoma Evaluation Study (ADAGES): Racial differences in optic disc hemorrhage and beta-zone parapapillary atrophy. Ophthalmology 2016; 123: 1476–83.113Zhang X, Loewen N, Tan O, et al.; Advanced Imaging for Glaucoma Study Group. Predicting development of glaucomatous visual field conversion using baseline fourier-domain optical coherence tomography. Am J Ophthalmol 2016; 163: 29–37.114Yu M, Lin C, Weinreb RN, Lai G, Chiu V, Leung CK. Risk of visual field progression in glaucoma patients with progressive retinal nerve fiber layer thinning: A 5-year prospective study. Ophthalmology 2016; 123: 1201–10.115Belghith A, Medeiros FA, Bowd C, et al. Structural change can be detected in advanced-glaucoma eyes. Invest Ophthalmol Vis Sci 2016;57: OCT511–8. 116Baril C, Vianna JR, Shuba LM, Rafuse PE, Chauhan BC, Nicolela MT. Rates of glaucomatous visual field change after trabeculectomy. Br J Ophthalmol. 2016 Nov 3. pii: bjophthalmol-2016-308948. doi: 10.1136/bjophthalmol-2016-308948. [Epub ahead of print]117Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology 2004; 111: 1641–8.118Whitacre MM, Stein RA, Hassanein K. The effect of corneal thickness on applanation tonometry. Am J Ophthalmol 1993; 115: 592-6.119Kerrigan-Baumrind LA, Quigley HA, Pease ME, Kerrigan DF, Mitchell RS. Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons. Invest Ophthalmol Vis Sci 2000; 41: 741–8. 120Akagi T, Iida Y, Nakanishi H, et al. Microvascular density in glaucomatous eyes with hemifield visual field defects: An optical coherence tomography angiography study. Am J Ophthalmol 2016; 168: 237–49. 121Heijl A, Leske MC, Bengtsson B, et al.; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268–79.122Tanihara H, Inoue T, Yamamoto T, et al. Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: A report of 2 randomized clinical trials. JAMA Ophthalmol 2015; 133: 755–61. 123Bacharach J, Dubiner HB, Levy B, Kopczynski CC, Novack GD; AR-13324-CS202 Study Group. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology 2015; 122: 302–7. 124Tanihara H, Inoue T, Yamamoto T, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol 2016; 94: e26–34.125Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol 2012; 153: 789e2–803e2. 126Rulli E, Biagioli E, Riva I, et al. Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures: a systematic review and meta-analysis. JAMA Ophthalmol 2013; 131: 1573–82. 127Ayyala RS, Chaudhry AL, Okogbaa CB, Zurakowski D. Comparison of surgical outcomes between canaloplasty and trabeculectomy at 12 months’ follow-up. Ophthalmology 2011; 118: 2427–33. 128Lam DS, Lai JS, Tham CC, Chua JK, Poon AS. Argon laser peripheral iridoplasty versus conventional systemic medical therapy in treatment of acute primary angle-closure glaucoma : a prospective, randomized, controlled trial. Ophthalmology 2002; 109: 1591–6.129Ritch R, Tham CC, Lam DS. Long-term success of argon laser peripheral iridoplasty in the management of plateau iris syndrome. Ophthalmology 2004; 111: 104–8.130Azuara-Blanco A, Burr J, Ramsay C, et al. Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial. Lancet 2016; 388: 1389–97.131Teekhasaenee C, Ritch R. Combined phacoemulsification and goniosynechialysis for uncontrolled chronic angle-closure glaucoma after acute angle-closure glaucoma. Ophthalmology 1999;106: 669–75.132Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016; 123: 1036–42. 133Jiang Y, Friedman DS, He M, Huang S, Kong X, Foster PJ. Design and methodology of a randomized controlled trial of laser iridotomy for the prevention of angle closure in southern China: the Zhongshan Angle Closure Prevention trial. Ophthalmic Epidemiol 2010; 17: 321–32. 134Gudmundsdottir BS, Petursdottir D, Asgrimsdottir GM, et al. γ-Cyclodextrin nanoparticle eye drops with dorzolamide: effect on intraocular pressure in man. J Ocul Pharmacol Ther 2014; 30: 35–41. 135Somner JE, Sii F, Bourne RR, Cross V, Burr JM, Shah P. Moving from PROMs to POEMs for glaucoma care – a qualitative scoping exercise. Invest Ophthalmol Vis Sci 2012;53:5940–7.136Wang JW, Chen SD, Zhang XL, Jonas JB. Retinal microglia in glaucoma. J Glaucoma 2016;25:459–65.137Golzan SM, Morgan WH, Georgevsky D, Graham SL. Correlation of retinal nerve fibre layer thickness and spontaneous retinal venous pulsations in glaucoma and normal controls. PLoS One 2015; 10: e0128433.138Wang YX, Jiang R, Wang NL, Xu L, Jonas JB. Acute peripapillary retinal pigment epithelium changes associated with acute intraocular pressure elevation. Ophthalmology 2015; 122: 2022–8.139Fortune B, Reynaud J, Hardin C, Wang L, Sigal IA, Burgoyne CF. Experimental glaucoma causes optic nerve head neural rim tissue compression: A potentially important mechanism of axon injury. Invest Ophthalmol Vis Sci 2016; 57: 4403–11.140Wolosin JM, Ritch R, Bernstein AM. Is autophagy dysfunction a key to exfoliation glaucoma? J Glaucoma 2016;Epub Dec 20141Lindsey JD, Duong-Polk KX, Hammond D, Chindasub P, Leung CK, Weinreb RN. Differential protection of injured retinal ganglion cell dendrites by brimonidine. Invest Ophthalmol Vis Sci 2015; 56: 1789–804.142Perera SA, Ting DS, Nongpiur ME, et al. Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population. Clin Ophthalmol 2016; 10: 757–64. FiguresFig. 1Histo-photograph showing the ciliary body (“1”) in the posterior chamber as site of the production of aqueous humour; “2”: Gap between the iris (“3”) and the lens (“4”) as connecting path for the aqueous humour to percolate from the posterior chamber into the anterior chamber through the pupil (“5”). The anterior chamber angle is located between the peripheral cornea (“6”) and the peripheral iris and contains the trabecular meshwork (“7”) and Schlemm?s canal (“8”) as outflow system for the aqueous humour (in addition to the uveoscleral outflow). Fig. 2Gonioscopic view on the open anterior chamber angle in an eye with pigment dispersion syndrome, showing the hyperpigmented Schwalbe?s line (Sampaolesi?s line as the end of Descemet?s membrane) (black arrows), the hyperpigmented trabecular meshwork (red arrows) and the scleral spur (blue arrows) as the posterior end of the anterior chamber angle; while arrow: peripheral iris; green arrow: pupillary marginFig. 3Ophthalmoscopic photograph of a small optic disc without cupping (left image) and of primary macrodisc (right image) with a pseudo-glaucomatous but physiologic macrocup; Note: the neuroretinal rim has its physiologic shape with the widest part in the inferior disc region (“I”), followed by the superior disc region (“S”), the nasal disc area (“N”), and finally the temporal disc region (“T”) (so called ISNT-rule) Fig. 4Series of optic discs from a normal finding (Fig. 4a) to early glaucoma (Fig. 4b), and eventually end-stage of glaucoma (Fig. 4f)Fig. 5a, bFig. 5a: Ophthalmoscopic photograph of the retinal nerve fiber layer of a normal left eye, with the best visibility (and thickest part) retinal nerve fiber layer in the temporal inferior region, followed by the temporal superior region, the nasal superior region, and finally the nasal inferior region. Fig. 5b: Ophthalmoscopic photograph of the retinal nerve fiber layer of a glaucomatous eye with localized defect (between white arrows) and a diffusely decreased visibility (and thickness) of the retinal nerve fiber layerFig. 5bFig. 6Histo-photograph showing a normal optic nerve head with the lamina cribrosa (between green stars) as the bottom of the optic cup (“A”) and the neuroretinal rim (“B”) containing the retinal ganglion cell axons; “C” orbital cerebrospinal fluid space between the pia mater of the optic nerve (“D”) and the dura mater of the optic nerve (“E”)Fig. 7Slit lamp assisted biomicroscopy of the lens surface of an eye with exfoliation syndrome and with the pupil medically dilated, showing the dandruff material in the central region of the lens surface (white arrows) and in the peripheral region (red arrows), leaving free an intermediary zone corresponding to the rubbing of the posterior pupillary margin on the lens surface ................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
- glaucoma progression timeline
- glaucoma progression rate
- glaucoma progression to blindness
- low tension glaucoma treatment
- normal tension glaucoma progression
- normal tension glaucoma
- treatment for normal tension glaucoma
- low tension glaucoma study
- low tension glaucoma meds
- normal tension glaucoma treatment
- low tension glaucoma symptoms
- low tension glaucoma and blindness